18 Results

People

  1. Brentjens
    Brentjens
  2. Park
    Park
  3. Palomba
    Palomba
  4. Sadelain
    Sadelain
  5. Halton
    Halton
  6. Riviere
    Riviere
  7. Giralt
    Giralt
  8. Perales
    Perales
  9. Sauter
    Sauter
  10. Van Den Brink
    Van Den Brink

Groups

  1. Adult Leukemia (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Executive Committee, Center for Hematologic Malignancies (18)
  5. GSK Faculty (18)
  6. Hematologic Malignancies Research (18)
  7. Hematologic Malignancies, Division of (18)
  8. Sloan Kettering Institute Faculty (13)
  9. Immunology Program Faculty (11)
  10. Bone Marrow Transplant (10)
  1. "Hematologic Malignancies Research"
  2. "Renier Brentjens"
  3. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Adult Leukemia (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Executive Committee, Center for Hematologic Malignancies (18)
  5. GSK Faculty (18)
  6. Hematologic Malignancies Research (18)

More Groups

People
  1. Renier Brentjens (18)
  2. Jae Park (10)
  3. Maria Palomba (9)
  4. Michel Sadelain (9)
  5. Elizabeth Halton (8)
  6. Isabelle Riviere (8)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (6)
  5. 2018 (2)
  6. 2017 (1)

More Years

Publications
  1. Blood (8)
  2. Biology of Blood and Marrow Transplantation (2)
  3. Bone Marrow Transplantation (1)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
  5. Hematological Oncology (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. Nature Publishing Group (4)
  3. Elsevier Inc. (3)
  4. American Society of Clinical Oncology (1)
  5. Elsevier Science, Inc. (1)
  6. Wiley Blackwell (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
    Journal Article

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy
    Meeting Abstract

    Smith, M.; Littmann, E.; Slingerland, J.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Peled, J. U.; Park, J.; O'Cearbhaill, R.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Conditioning prior to CD19-specific CAR (19-28Z) T cells predicts response and survival in pediatric relapse/refractory (R/R) B-ALL
    Meeting Abstract

    Curran, K.; Margossian, S.; Kernan, N.; Prockop, S.; Boulad, F.; Cancio, M.; Szenes, V.; Kung, A.; Boelens, J. J.; O'Reilly, R.; more...
    Bone Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save